Thursday, September 06, 2018 8:41:59 AM
- Industry veteran to lead and execute operations for pivotal Phase 3 SIERRA trial for Iomab-B and Actinium's continued expansion of its CD33 program and focus on targeted conditioning for BMT
"Dr. Daly is a seasoned industry veteran with more than 20 years of relevant experience in clinical operations, clinical research and product development, having worked for pharmaceutical, biotechnology and contract research organizations, worldwide," stated Dr. Berger. "He has considerable experience in successfully managing clinical operations of large, global clinical trials as evidenced by the 7,000 patient, 450-site Phase 3 trial he led across 30 countries while at Portola that resulted in the approval of Betrixaban. Dr. Daly's clinical operations expertise, as well as his experience in the field of hematologic malignancies, makes Dr. Daly a perfect fit for this position. I look forward to working with Dr. Daly in continuing to establish Actinium as the leader in targeted conditioning for bone marrow transplant."
Dr. Daly stated, "Throughout my career I have managed and progressed large, multi-center, international clinical trials including those that have supported approvals in areas of high unmet patient need. I was struck by the pedigree of Actinium's drug candidates and the breadth of clinical evidence supporting their use in targeting conditioning for bone marrow transplant and hematologic indications. I am excited to join Actinium now, given the positive momentum of the SIERRA trial for Iomab-B following the positive DMC safety analysis and the recent expansion of our CD33 program to targeted conditioning for high-risk MDS patients, multiple myeloma and in novel combinations for difficult to treat patient populations. I look forward to working with my colleagues at Actinium to successfully complete the SIERRA trial, prepare for a BLA submission and continue to build a best-in-class CD33 program. This is clearly an exciting and critical time for Actinium and I am honored to be on board and to contribute to the Company's mission."
Sandesh Seth, Actinium's Chairman and CEO said, "Actinium has evolved to a highly differentiated biotechnology company with a multi-target clinical pipeline focused on targeted conditioning to provide more patients with access to potentially curative bone marrow transplant and improving patient outcomes from BMT. Utilizing our antibody radio-conjugate approach, our clinical development team has found multiple ways to drive synergy and expansion across our pipeline as evidenced by first-in-class initiatives such as our Actimab-MDS trial, the first CD33 targeted conditioning trial for this patient population, and Actimab-M, the first CD33 targeting program and alpha-particle in patients with multiple myeloma. We are confident that additional opportunities exist that our ARC approach is ideally suited for and the addition of Dr. Daly to the Actinium team will allow us to efficiently and effectively capitalize on these opportunities. I am confident that Dr. Daly will make an immediate impact on our pivotal Phase 3 SIERRA trial and lasting contributions to Actinium's growth."
Prior to joining Actinium, Dr. Daly served as Vice President, Clinical, at CTI BioPharma, where he led research and development activities for Clinical Operations supporting the company's two Phase 3 programs for Pacritinib, a JAK2/FLT3 inhibitor for patients with Myelofibrosis. Previously, Dr. Daly was Vice President, Development Operations at Durata Therapeutics, Inc., until its acquisition by Actavis, plc. At Durata, Dr. Daly managed multiple departments including all R&D, Clinical Monitoring and Operations, Project Management, Biostatistics and Data Management supporting Dalbavancin, a lipoglycopeptide antibiotic approved for patients infected with methicillin-resistance Staphylococcus aureus. Dr. Daly served as Executive Director, Clinical Operations and Head, Global Medical Sciences and Medical Affairs for Portola Pharmaceuticals, Inc. While at Portola, Dr. Daly managed a 7,000 patient, 450-site Phase 3 trial in 30 countries that led to the approval of the Factor Xa Inhibitor Betrixaban for patients with venous thrombosis. Dr. Daly also directed Portola's activities in oncology for an orally available kinase inhibitor aimed at hematologic cancers and inflammatory disorders. During Dr. Daly's career, he also gained valuable clinical research, clinical operations and product experience at companies including KAI Pharmaceuticals, Inc., Artisan Pharma, Inc., Theravance Biopharma, Inc., Millennium Pharmaceuticals, Inc., DuPont Pharmaceuticals Company and KOS Pharmaceuticals, Solvay Pharmaceuticals and SmithKline Beecham Pharmaceuticals.
Dr. Daly received his Ph.D. in pharmacology from the Medical College of Pennsylvania (now Drexel University School of Medicine), a Master of Science in biology from Drexel University and a Bachelor of Arts degree in biology from Glassboro State College (now Rowan University). He has authored more than 30 publications and has been a frequent presenter at major medical meetings.
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for potentially superior targeted conditioning of the bone marrow prior to a bone marrow transplant and for the targeting and killing of cancer cells. The Company's targeted Antibody Radio-Conjugates (ARCs), combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes. Actinium is developing a pipeline of clinical-stage ARCs targeting CD45 and CD33 for patients with a broad range of hematologic malignancies.
Iomab-B, Actinium's lead product candidate, is currently enrolling patients in a pivotal Phase 3 trial. Iomab-B combines the anti-CD45 monoclonal antibody BC8 labeled with iodine-131 and is designed to condition the bone marrow prior to a bone marrow transplant without the need for intense chemotherapy in patients with relapsed or refractory acute myeloid leukemia (AML) of age 55 or older. Actinium's pipeline also includes a potentially best-in-class CD33 program with our ARC comprised of the anti-CD33 antibody lintuzumab labeled with the alpha-particle emitter actinium-225. Its CD33 program is currently being studied in Phase 2 and Phase 1 clinical trials for patients with AML, myelodysplastic syndrome (MDS) and multiple myeloma.
Actinium is also developing its proprietary Actinium Warhead Enabling (AWE) technology platform to utilize the highly differentiated radioisotope actinium-225 with a wide range of targets. AWE is being utilized in a collaborative research partnership with Astellas Pharma, Inc.
More information is available at http://www.actiniumpharma.com and our Twitter feed @ActiniumPharma, http://www.twitter.com/actiniumpharma.
Forward-Looking Statements for Actinium Pharmaceuticals, Inc.
This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the private securities litigation reform act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with preliminary study results varying from final results, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.
Contact:
Actinium Pharmaceuticals, Inc.
Steve O'Loughlin
Principal Financial Officer
mailto://soloughlin@actiniumpharma.com
Investor Relations
Rx Communications Group
Susan A. Noonan
212 966-3650
mailto://investorrelations@actiniumpharma.com
View original content: http://www.prnewswire.com/news-releases/actinium-appoints-robert-n-daly-phd-to-newly-created-role-of-vice-president-head-of-clinical-operations-300707708.html
Recent ATNM News
- Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology • PR Newswire (US) • 09/20/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/05/2024 09:15:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 11:30:34 AM
- Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S. • PR Newswire (US) • 08/05/2024 11:00:00 AM
- Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications • PR Newswire (US) • 08/01/2024 12:00:00 PM
- Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University • PR Newswire (US) • 07/25/2024 12:45:00 PM
- Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US • PR Newswire (US) • 07/25/2024 11:30:00 AM
- Actinium Presents First Ever Data Demonstrating Actimab-A in Combination with Leading Menin Inhibitors Leads to Anti-Tumor Control and Potent Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress • PR Newswire (US) • 06/17/2024 12:00:00 PM
- Actinium Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial • PR Newswire (US) • 06/14/2024 12:30:00 PM
- Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting • PR Newswire (US) • 06/11/2024 12:30:00 PM
- Actinium Highlights Mutation Data from the Phase 3 SIERRA Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting • PR Newswire (US) • 06/10/2024 12:30:00 PM
- Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity • PR Newswire (US) • 05/15/2024 12:30:00 PM
- Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phas • PR Newswire (US) • 05/14/2024 10:38:00 PM
- Actinium Announces Multiple Abstracts Highlighting its Antibody Radiation Conjugates Iomab-B and Actimab-A and Novel Linker Technology for Solid Tumors Accepted for Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting • PR Newswire (US) • 05/13/2024 12:30:00 PM
- Actinium Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern • PR Newswire (US) • 05/07/2024 12:00:00 PM
- Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting • PR Newswire (US) • 04/18/2024 12:00:00 PM
- Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation at the 50th European Bone Marrow Transplant Annual • PR Newswire (US) • 04/01/2024 12:00:00 PM
- Actinium Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy • PR Newswire (US) • 03/26/2024 11:18:00 AM
- Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand • PR Newswire (US) • 03/11/2024 11:30:00 AM
- Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMT • PR Newswire (US) • 02/26/2024 12:30:00 PM
- Actinium Highlights Improved Survival with Iomab-B in TP53 Positive Relapsed Refractory Acute Myeloid Leukemia Patients in the SIERRA Trial and Other Presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIB • PR Newswire (US) • 02/23/2024 12:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/09/2024 09:30:19 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/06/2024 05:15:04 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/02/2024 10:03:47 PM
- Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® • PR Newswire (US) • 01/02/2024 12:30:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM